7L3N

SARS-CoV 2 Spike Protein bound to LY-CoV555

Summary for 7L3N

• Entry DOI: 10.2210/pdb7l3n/pdb
• EMDB information: 23156
• Descriptor: Spike glycoprotein, LY-CoV555 Fab heavy chain, LY-CoV555 Fab light chain, ... (5 entities in total)
• Functional Keywords: glycoprotein, viral protein-immune system complex, viral protein/immune system
• Biological source: Severe acute respiratory syndrome coronavirus 2 (2019-nCoV); More
• Total number of polymer chains: 5
• Total formula weight: 475782.79

Authors

Goldsmith, J.A.,McLellan, J.S. (deposition date: 2020-12-18, release date: 2021-02-03, Last modification date: 2024-10-23)

Primary citation

Jones, B.E.,Brown-Augsburger, P.L.,Corbett, K.S.,Westendorf, K.,Davies, J.,Cujec, T.P.,Wiethoff, C.M.,Blackbourne, J.L.,Heinz, B.A.,Foster, D.,Higgs, R.E.,Balasubramaniam, D.,Wang, L.,Bidshahri, R.,Kraft, L.,Hwang, Y.,Zentelis, S.,Jepson, K.R.,Goya, R.,Smith, M.A.,Collins, D.W.,Hinshaw, S.J.,Tycho, S.A.,Pellacani, D.,Xiang, P.,Muthuraman, K.,Sobhanifar, S.,Piper, M.H.,Triana, F.J.,Hendle, J.,Pustilnik, A.,Adams, A.C.,Berens, S.J.,Baric, R.S.,Martinez, D.R.,Cross, R.W.,Geisbert, T.W.,Borisevich, V.,Abiona, O.,Belli, H.M.,de Vries, M.,Mohamed, A.,Dittmann, M.,Samanovic, M.,Mulligan, M.J.,Goldsmith, J.A.,Hsieh, C.L.,Johnson, N.V.,Wrapp, D.,McLellan, J.S.,Barnhart, B.C.,Graham, B.S.,Mascola, J.R.,Hansen, C.L.,Falconer, E.
LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection.
Biorxiv, 2020

PubMed Abstract: SARS-CoV-2 poses a public health threat for which therapeutic agents are urgently needed. Herein, we report that high-throughput microfluidic screening of antigen-specific B-cells led to the identification of LY-CoV555, a potent anti-spike neutralizing antibody from a convalescent COVID-19 patient. Biochemical, structural, and functional characterization revealed high-affinity binding to the receptor-binding domain, ACE2 binding inhibition, and potent neutralizing activity. In a rhesus macaque challenge model, prophylaxis doses as low as 2.5 mg/kg reduced viral replication in the upper and lower respiratory tract. These data demonstrate that high-throughput screening can lead to the identification of a potent antiviral antibody that protects against SARS-CoV-2 infection.

PubMed: 33024963
DOI: 10.1101/2020.09.30.318972

Experimental method

ELECTRON MICROSCOPY (3.27 Å)